TrialPloS one2013

RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.

Dana Keilty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.